Abstract: 【Objective】 To compare the clinical efficacy and safety of Tenofovir Disoproxil Fumarate (TDF) and Entecavir (ETV) in the Nucleoside-Analogues (NA) for NA naive chronic hepatitis B patients(CHB). 【Methods】 33 NA-naived CHB patients treated with TDF(TDF group ) and 65 with ETV (ETV group ) in our follow-up clinic were retrospectively investigated. HBV DNA levels

the cumulative rate of undetectable HBV DNA and ALT normalization

incidences of adverse events were evaluated at week 0

4

12

24

36

48

60. 【Results】 At 4th week

HBV DNA level was significantly lower in ETV group than in TDF group (TDF:4.26 ± 1.37 vs ETV: 3.47 ± 1.06 log10 IU/ml

P = 0.005)

while no difference was found in other time. The differences between the two groups in the cumulative rate of undetectable HBV DNA

ALT normalization rate were not statistically significant (P = 0.114

P = 0.656). HBV DNA levels persistent declined and the rate of undetectable HBV DNA continued rise in each group and the differences were statistically significant before in the first 24 weeks(all P < 0.05)

the same as ALT normalization rate in the first 12 weeks treatment (all P < 0.05). There was no significant differences in the incidences of CK more than 2ULN in TDF and ETV. 【Conclusions】 For NA naive CHB patients in Mailand China

both TDF and ETV can suppress HBV DNA replication very quickly

with a high rate of ALT normalization and lower rate of adverse events.